[HTML][HTML] Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell lung cancer
B Melosky, S Banerji, N Blais, Q Chu… - Current …, 2020 - ncbi.nlm.nih.gov
Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell
lung cancer - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …
lung cancer - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …
SHOC2 is a critical modulator of sensitivity to EGFR–TKIs in non–small cell lung cancer cells
H Terai, J Hamamoto, K Emoto, T Masuda… - Molecular Cancer …, 2021 - AACR
EGFR mutation-positive patients with non–small cell lung cancer (NSCLC) respond well to
treatment with EGFR–tyrosine kinase inhibitors (EGFR–TKI); however, treatment with EGFR …
treatment with EGFR–tyrosine kinase inhibitors (EGFR–TKI); however, treatment with EGFR …
The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy
PL Su, JY Chen, CY Chu, YL Chen, WL Chen, KY Lin… - Scientific reports, 2022 - nature.com
Neoadjuvant immunotherapy and chemotherapy have improved the major pathological
response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC) …
response (MPR) in patients with early-stage operable non-small cell lung cancer (NSCLC) …
[HTML][HTML] Lymecycline reverses acquired EGFR-TKI resistance in non–small-cell lung cancer by targeting GRB2
Y Chen, J Wu, H Yan, Y Cheng, Y Wang, Y Yang… - Pharmacological …, 2020 - Elsevier
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) were first-line
treatments for NSCLC patients with EGFR-mutations. However, about 30% of responders …
treatments for NSCLC patients with EGFR-mutations. However, about 30% of responders …
Clinical utility of liquid biopsy (cell-free DNA) based EGFR mutation detection post treatment initiation as a disease monitoring tool in patients with advanced EGFR …
Introduction Plasma cfDNA-based mutation analysis has shown disease-monitoring
potential in various cancers. We assessed the potential of cfDNA-based EGFR mutation …
potential in various cancers. We assessed the potential of cfDNA-based EGFR mutation …
Lansoprazole Alone or in Combination With Gefitinib Shows Antitumor Activity Against Non-small Cell Lung Cancer A549 Cells in vitro and in vivo
X Zhao, N Zhang, Y Huang, X Dou, X Peng… - Frontiers in Cell and …, 2021 - frontiersin.org
Lansoprazole (Lpz) is an FDA-approved proton pump inhibitor (PPI) drug for the therapy of
acid-related diseases. Aiming to explore the new application of old drugs, we recently …
acid-related diseases. Aiming to explore the new application of old drugs, we recently …
Treatment of advanced non-small-cell lung cancer: First line, maintenance, and second line–Indian consensus statement update (Under the aegis of Lung Cancer …
K Prabhash, A Vora, S Limaye, TP Sahoo… - Cancer Research …, 2021 - journals.lww.com
The management of patients with advanced non-small-cell lung cancer (NSCLC) is
becoming increasingly complex, with the identification of driver mutations/rearrangements …
becoming increasingly complex, with the identification of driver mutations/rearrangements …
Epidermal growth factor receptor mutations
EM McLoughlin, RD Gentzler - Thoracic surgery clinics, 2020 - thoracic.theclinics.com
Background The discovery of the epidermal growth factor receptor (EGFR) and development
of targeted drugs have led to substantial gains in the treatment of non–small cell lung cancer …
of targeted drugs have led to substantial gains in the treatment of non–small cell lung cancer …
Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for …
MG Denis, J Bennouna - Cancer Management and Research, 2020 - Taylor & Francis
Non-small cell lung cancer (NSCLC) is one of the most efficient models for precision
medicine in oncology. The most appropriate therapeutic for the patient is chosen according …
medicine in oncology. The most appropriate therapeutic for the patient is chosen according …
Outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after EGFR tyrosine kinase inhibitors resistance: A systematic review and …
J Xu, L Xu, B Wang, W Kong, Y Chen, Z Yu - Frontiers in Oncology, 2022 - frontiersin.org
Background Lung adenocarcinoma can transform into small-cell lung cancer (SCLC) when
resistance to tyrosine kinase inhibitors (TKIs) develops. Approximately 3% to 10% of …
resistance to tyrosine kinase inhibitors (TKIs) develops. Approximately 3% to 10% of …